Comparator: efavirenz — Competitive Intelligence Brief

Comparator: efavirenz (Comparator: efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease / Virology.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Comparator: efavirenz (Comparator: efavirenz) — Merck Sharp & Dohme LLC. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: efavirenz TARGET	Comparator: efavirenz	Merck Sharp & Dohme LLC	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
TDF/3TC/EFV	TDF/3TC/EFV	Peking Union Medical College Hospital	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Lopinavir/ritonavir + nevirapine	Lopinavir/ritonavir + nevirapine	Amsterdam UMC, location VUmc	marketed	Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
rilpivirina + emtricitabina + tenofovir	rilpivirina + emtricitabina + tenofovir	Hospital Universitari Vall d'Hebron Research Institute	marketed	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
Tenofovir (TDF)	Tenofovir (TDF)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase; Hepatitis B polymerase
Zidovudine (drug)	Zidovudine (drug)	Johann Wolfgang Goethe University Hospital	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class